CSL (ASX:CSL) share price slumps despite new board appointment

The company's shares are continuing the week lower.

| More on:
a doctor in white coat slumps against a window, head on hand, gazing down in dejection.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The CSL Limited (ASX: CSL) share price is in the red today following the inclusion of a new member to its board.

At the time of writing, the global biotech's shares are down 0.7% to $295.40. In comparison, the S&P/ASX 200 Index (ASX: XJO) is also down 1.06% to 7,502 points.

CSL strengthens its team

Investors appear to be unmoved by the company's latest news, selling CSL shares ahead of its FY21 full-year results tomorrow.

In today's release, CSL advised it has appointed Professor Duncan Maskell as an independent non-executive director, effective from 18 August.

Professor Maskell brings a wealth of knowledge from the private sector, particularly in the commercialisation of research initiatives.

He has co-founded several biotech companies such as Arrow Therapeutics and Discuva. Arrow was sold to British-Swedish multinational pharmaceutical and biotechnology giant AstraZeneca while antibiotic innovation company Summit Therapeutics purchased Discuva.

Professor Maskell is currently serving as vice-chancellor of the University of Melbourne. Prior to this, he held the role of senior pro-vice-chancellor at the University of Cambridge in the United Kingdom.

Previously, Professor Maskell also worked at the University of Oxford, Imperial College London and Wellcome Biotech.

CSL chair Dr Brian McNamee AO commented:

Professor Maskell is an exceptional addition to the CSL Board. He brings wide-ranging international experience in science and commerce, developed across a rich 30-year career in research, academia and entrepreneurship. These areas represent the core of what we do at CSL and his contribution will strengthen the Board's range of experience.

Professor Maskell has a Master of Arts and a Doctor of Philosophy from the University of Cambridge.

About the CSL share price

Over the course of the past 12 months, CSL shares have taken investors on a rollercoaster ride but are up just 5.13%. The company's shares are currently sitting just above the middle of their 52-week range of $242.00 to $320.42.

On valuation grounds, CSL is the third-largest company on the ASX with a market capitalisation of roughly $134.45 billion.

Motley Fool contributor Aaron Teboneras owns shares of CSL Ltd. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

Stock market chart in green with a rising arrow symbolising a rising share price.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a massive day for the ASX 200, with a new all-time high recorded.

Read more »

A man sits thoughtfully on the couch with a laptop on his lap.
Technology Shares

This ASX tech stock rocketed 60% in March! Can it keep on delivering?

After soaring in March, the ASX tech stock is now up 169% since this time last year.

Read more »

Broker Notes

Brokers name 3 ASX shares to buy now

Here's why brokers are feeling bullish about these three shares this week.

Read more »

A young man clasps his hand to his head with his eyes closed and a pained expression on his face as he clasps a laptop computer in front of him, seemingly learning of bad news or a poor investment.
Share Fallers

Why Burgundy Diamond Mines, Clarity Pharmaceuticals, EML, and Zip are sinking today

These ASX shares are ending the week in the red. But why?

Read more »

A young women pumps her fists in excitement after seeing some good news on her laptop.
Share Gainers

Why Mesoblast, Newmont, Pilbara Minerals, and Platinum shares are jumping

These ASX shares are ending the week strongly. But why?

Read more »

a young boy dressed up in a business suit and tie has a cute grin and holds two fingers up.
Opinions

2 of my top ASX 200 shares to consider buying before April

I would happily exchange dollars for these two shares right now.

Read more »

Father in the ocean with his daughters, symbolising passive income.
Dividend Investing

I'd spend $8k on these ASX 200 shares today to target a $6,102 annual passive income

I believe these ASX 200 shares will continue rewarding passive income investors for years to come.

Read more »

Three businesspeople leap high with the CBD in the background.
Share Market News

Boom! ASX 200 blasts to new record highs

ASX 200 investors just sent the benchmark index into uncharted territory.

Read more »